Valuation: Agenus Inc.

Market Cap 330M 285M 267M 243M 457M 31.51B 465M 3.13B 1.23B 15.78B 1.24B 1.21B 52.44B P/E 2026 *
10.8x
P/E 2027 * -29.9x
Enterprise Value 330M 285M 267M 243M 457M 31.51B 465M 3.13B 1.23B 15.78B 1.24B 1.21B 52.44B EV / Sales 2026 *
2.35x
EV / Sales 2027 * 2.4x
Free-Float
93.77%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agenus Inc.

1 day+4.57%
1 week+5.17%
Current month-2.40%
1 month+46.11%
3 months+104.47%
6 months+150.68%
Current year+133.12%
1 week 6.36
Extreme 6.36
7.46
1 month 4.78
Extreme 4.78
8.85
Current year 2.71
Extreme 2.71
8.85
1 year 2.71
Extreme 2.71
8.85
3 years 1.38
Extreme 1.38
32
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 30/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 31/10/2021
Director TitleAgeSince
Chairman 73 03/11/2010
Director/Board Member 78 06/08/2024
Director/Board Member 73 07/10/2020
Date Insider Type Main position Quantity % Market Cap.
10/08/26 Free

Chief Executive Officer

1,971,500 4.4054%
05/08/26 Free

Director

50,000 0.1117%
05/08/26 Free

Director

50,000 0.1117%
Change 5-day change 1-year change 3-year change Capi.($)
+4.57%+5.17%+58.10%-72.89% 330M
-1.78%-1.68%+1.48%+15.31% 48.42B
+0.85%-0.70%+460.88%+563.55% 43.66B
-2.40%-0.23%+8.13%+71.41% 39.51B
-2.01%-0.85%+23.85%+8.73% 38.95B
-0.50%+0.85%+20.60%+49.65% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+118.09% 16.15B
+0.49%+0.92%+4.11%+23.67% 14.16B
-0.43%+4.70%+78.74%+33.31% 13.37B
Average -0.14%+0.96%+75.80%+90.09% 26.35B
Weighted average by Cap. -0.91%+0.60%+95.78%+132.67%

Financials

2026 *2027 *
Net sales 140M 121M 114M 104M 195M 13.42B 198M 1.33B 522M 6.72B 527M 515M 22.33B 137M 119M 111M 101M 191M 13.13B 194M 1.31B 511M 6.58B 516M 504M 21.86B
Net income 35.2M 30.4M 28.57M 25.98M 48.85M 3.37B 49.65M 335M 131M 1.69B 132M 129M 5.6B -26.1M -22.54M -21.18M -19.26M -36.22M -2.5B -36.82M -248M -97.05M -1.25B -97.99M -95.87M -4.15B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
14/08/26 US$7.320 +4.57% 1,251,966
13/08/26 US$7.000 +1.45% 624,951
12/08/26 US$6.900 +1.02% 1,154,187
11/08/26 US$6.830 -2.43% 1,373,565
10/08/26 US$7.000 +0.57% 1,923,046
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.320USD
Average target price
19.50USD
Spread / Average Target
+166.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock